DRUG Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -9.07%, SMA50 -7.26%, SMA200 48.14%). The stock’s 14-day RSI is 42.67 (neutral), while the ATR of 6.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -38.61% below its high and over 227.81% above its low. Average 10-day trading volume of 126.71 thousand shares is below the 3-month average of 199.19 thousand, indicating normal recent market interest.

Bright Minds Biosciences Inc. has 7.09 million shares outstanding. The public float is 3.01 million shares, elevated short interest at 4.09% of float. This equals 197.86 thousand shares. The short ratio is 4.06 days. Institutional investors hold 95.36% of the float. Insiders own 22.42%.

Bright Minds Biosciences Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.82. This means the shares are trading above this model’s fair value.

Bright Minds Biosciences Inc. generated EPS of -$1.24 over the past year. Five-year average earnings growth is -35.46%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $147.00 to $72.00. The high target offers 93.5% upside. The low target suggests -5.23% downside. The mean target is $102.00. This offers 34.26% upside. Bright Minds Biosciences Inc. earnings surprise history is frequent misses against expectations. The quarter that ended December 23, 2025, missed forecasts by -54.92%. The prior quarter beat by -10.17%. Over the last six quarters, Apple has recorded several small beats. These include -72.94% in December 30, 2024.

Bright Minds Biosciences Inc. (NASDAQ:DRUG) closed at $75.97 USD, gaining $2.89 (3.95%) from the previous close of $73.08. The stock is currently mid-range between its 52-week high and low $23.18 and $123.75. With a market capitalization of about $591.58 million, Bright Minds Biosciences Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.49). Key stats such as the average daily volume over the past year has been around 205.18 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, BC, Bright Minds Biosciences Inc. operates in the Healthcare sector and the Biotechnology industry. Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases.

Our AI price prediction model suggests that Bright Minds Biosciences Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.23%, with price expected at $69.72 by February 20, 2026, within a range of $63.84 to $75.71 3-Month Outlook: Projected fall of -86.02%, reaching $10.62 by May 06, 2026, with a range of $6.67 to $12.85. 1-Year Outlook: Projected gain of 23.04%, with price at $93.47 by February 05, 2027, within a range of $88.34 to $99.53.

Bright Minds Biosciences Inc. (NASDAQ:DRUG) shares are flat 6.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Bright Minds Biosciences Inc. trading at a premium to the broader market with a P/E of -67.79. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $97.18, suggesting 27.92% upside. Our AI forecast model points to short-term weakness (-8.23% over two weeks), a medium-term fall (-86.02% over three months), and a longer-term gain (23.04% over one year), with expected trading ranges indicating moderate volatility.

Bright Minds Biosciences Inc. trades at a P/E ratio of -67.79, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 12.75 reflecting a rich premium to book value. The P/FCF stands at -97.88, also below market averages. Compared to sector medians, Bright Minds Biosciences Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.